about
The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis.Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome.Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity.Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure.Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres.Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.Transarterial therapies for hepatocellular carcinoma.Radioembolization for hepatocellular carcinoma.Gene therapy of neoplastic liver diseases.Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application.Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI gradeResearch reporting standards for radioembolization of hepatic malignancies.Tracing transgene expression in cancer gene therapy: a requirement for rational progress in the field.Positron emission tomography and gene therapy: basic concepts and experimental approaches for in vivo gene expression imaging.Future therapies for hepatocellular carcinoma.New therapies for hepatocellular carcinoma.Long-term follow-up study of gastroduodenal lesions after radioembolization of hepatic tumorsYttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives.Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI gradeSpontaneous regression of hepatocellular carcinoma: three case reports and a categorized review of the literature.Spontaneous regression of hepatocellular carcinoma: a systematic review.Nonsurgical treatment for localized hepatocellular carcinoma.Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension.Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasionRadioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations.Integrating radioembolization ((90)Y microspheres) into current treatment options for liver tumors: introduction to the international working group report.Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers.Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver.Integrating radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases.Radioembolization for the treatment of liver tumors general principles.Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90.Chemoembolization and radioembolization.Transarterial chemoembolization and radioembolization.Evidence-based integration of selective internal radiation therapy into hepatocellular carcinoma management.Liver function considerations for post-selective internal radiation therapy resection (hepatocellular carcinoma and metastatic colorectal cancer).Immunological landscape and immunotherapy of hepatocellular carcinoma.The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma.
P50
Q33366601-47A4B820-8E87-431D-A0D5-860567C4C04CQ33495419-4EA72405-9AB9-4510-9D54-B6B6BB03F38CQ34506324-8049AA98-B62B-43F7-94A1-74879C4513F1Q34558284-53AEA56B-F879-4D26-9D32-C32792370C1AQ34609193-C681A2F4-B805-4641-B0C3-7E945CBC6954Q34621197-5340A579-6495-4B39-9ED4-AFB85E90FD22Q34622672-4975DD19-CAA8-47BF-8CD8-F9EC12771410Q34628257-D3DBD6C2-642B-412A-A7CC-C370E0D3E259Q34631431-425F0138-5128-4EDA-AD49-6E2A884130E7Q35024674-F10149D1-E0C6-46DB-BCBE-2E40058BE58FQ35055059-874C76C0-8168-4CA7-BD07-29C753F549ECQ35065472-FA7182BB-48A8-4D14-8056-E0DED2FC9288Q35111887-823EFDBC-9564-422A-B149-68177F15C8ABQ35555157-044F4584-B3FF-482E-B067-A2D6447643CDQ35840440-A567801B-D0FC-4964-BAC9-534F2348ED4BQ36096821-13D4A3B5-1F9A-481E-8E95-096FAD10749EQ36519041-225A55F6-F5E1-4F12-A573-6B7654BEB7D0Q36865115-27ACC73A-8914-4DCE-8A8F-8B03D61DB478Q37068157-9D101F51-5385-4B69-97D1-9EF144EEFE85Q37174913-5B60C043-4A48-4208-A643-D1EC57A936C8Q37248404-52D17529-D0F9-4FC7-A324-F9FAF51F8A49Q37412880-D9E74E7E-0664-4199-B717-0CA441EA126AQ37578521-8B5C7ED5-F88A-4803-9A8C-292B19232D2CQ37623505-AE28CABE-34F2-435A-ADDC-6B7FACF6E7ADQ37639132-494FFDAC-7DB0-4410-B557-281C3BB7CAA5Q37655092-55898974-2F93-4864-B5E0-463797558B11Q37771838-B487A783-4B1B-4F5D-9B87-9AA9202E3B37Q37799506-4E06A5BA-CB5A-4FD3-A94C-3D00C898D3ACQ37815366-9677650B-3FBB-4E17-9867-281DA568D9FAQ37833443-129892CF-8E91-4B01-B1AD-3F5040F5D98FQ37833444-B808F9CE-96B1-4B14-966A-B5AA86E932DCQ37987948-8640E47D-2B40-4FCE-8C40-164CEDDAE8ADQ38080501-1EE0424D-7FC4-4F7E-9A21-951838AFCB7BQ38101443-ACDC31CB-6F8B-4C60-974E-E1198BBB14D5Q38254703-0BB049A1-71C8-4490-BB31-89548BF9D548Q38264958-F2583EF4-29FD-43DB-83BE-562E8E0C56B0Q38283651-F00BD625-2D23-4BF4-84F2-46934F964BD8Q38283670-DB6224C7-5709-40DD-8860-37F9122115B5Q38611895-8981CE21-A1BE-4A84-83D9-35476B2FE25EQ38646109-F6D959E8-060B-4FAE-8FD6-A78F78E070F3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bruno Sangro
@ast
Bruno Sangro
@en
Bruno Sangro
@es
Bruno Sangro
@nl
Bruno Sangro
@sl
type
label
Bruno Sangro
@ast
Bruno Sangro
@en
Bruno Sangro
@es
Bruno Sangro
@nl
Bruno Sangro
@sl
prefLabel
Bruno Sangro
@ast
Bruno Sangro
@en
Bruno Sangro
@es
Bruno Sangro
@nl
Bruno Sangro
@sl
P106
P1153
7004456732
P21
P31
P496
0000-0002-4177-6417